{"classes":[{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"6.143","upperLimit":"24.143","value":"6.4"},{"comment":"Only one participant in this arm achieved a response. With a single observation event, a median time to response and confidence interval cannot be estimated.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"TTR was defined as the interval between the date of the first T-cell infusion and the earliest date of the first documented confirmed CR or confirmed PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received afamitresgene autoleucel 0.1x10\\^9 transduced cells","id":"OG000","title":"Afamitresgene Autoleucel, Group 1"},{"description":"Participants who received afamitresgene autoleucel 0.5-1.2x10\\^9 transduced cells","id":"OG001","title":"Afamitresgene Autoleucel, Group 2"},{"description":"Participants who received afamitresgene autoleucel 1.2-10x10\\^9 transduced cells","id":"OG002","title":"Afamitresgene Autoleucel, Group 3 + Expansion"},{"description":"Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.","id":"OG003","title":"Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel achieving CR or PR.","reportingStatus":"POSTED","timeFrame":"From afamitresgene autoleucel infusion until first documented confirmed CR or PR","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Weeks"}